By Connor Hart
Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.
The San Diego biopharmaceutical company said Monday it will obtain exclusive rights for the drug in all territories worldwide except Japan, where Takeda will reacquire exclusive rights. Under the updated agreement, each company is responsible for development costs in their respective regions, and both companies are eligible to receive royalty payments.
Chief Executive Kyle Gano said the new terms will streamline the collaboration structure, hopefully bringing the treatment to market faster.
Neurocrine and Takeda, which is headquartered in Osaka, Japan, entered an agreement to develop and commercialize compounds for treatment of depression and schizophrenia in 2020.
Osavampator is a potential treatment for major depressive disorder for patients who haven't benefited from treatment with at least one antidepressant in their current episode of depression, Neurocrine said. The company plans to initiate a Phase 3 trial for the drug in the first half.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 27, 2025 17:21 ET (22:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。